Cancer can often hide from treatments, making it hard to get rid of all cancer cells. Even after reaching remission with chemotherapy, a relatively small number of cancer cells can remain in your body that cannot be detected by traditional testing. This is called minimal residual disease, or MRD.2
There are now very sensitive and reliable tests to detect MRD, and it is important to get tested for MRD even after achieving remission. Ask your doctor if an MRD test is right for your child.1,2
If your child is in remission but tests positive for MRD, BLINCYTO® can help.1
Ask your child’s doctor if BLINCYTO® is right for treating their ALL.
During treatment with BLINCYTO®, your health care provider will check for symptoms, which can be suggestive of serious side effects that can be severe or life-threatening.
It is also important to notify your health care provider of any side effects you may be having. If certain side effects are observed, your health care provider may change the dose, or delay, or completely stop BLINCYTO® treatment.
These are not all of the possible side effects of BLINCYTO®.
Serious side effects that can occur during BLINCYTO® treatment include cytokine release syndrome (CRS), infusion reactions, and neurologic problems.
Tell your health care provider right away if you develop an infection or fever.
Tell your health care provider if you have any side effects that bother you or do not go away.
These are not all the possible side effects of BLINCYTO®.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.
The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are ongoing studies to confirm clinical benefit.
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39:47-57. 3. Food and Drug Administration. FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm603151.htm. Accessed October 7, 2019. 4. BLINCYTO® (blinatumomab) medication guide, Amgen.